Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 222

1.

Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment.

Budhu S, Schaer DA, Li Y, Toledo-Crow R, Panageas K, Yang X, Zhong H, Houghton AN, Silverstein SC, Merghoub T, Wolchok JD.

Sci Signal. 2017 Aug 29;10(494). pii: eaak9702. doi: 10.1126/scisignal.aak9702.

2.

GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.

Schaer DA, Budhu S, Liu C, Bryson C, Malandro N, Cohen A, Zhong H, Yang X, Houghton AN, Merghoub T, Wolchok JD.

Cancer Immunol Res. 2013 Nov;1(5):320-31. doi: 10.1158/2326-6066.CIR-13-0086.

3.

Enhanced responses to tumor immunization following total body irradiation are time-dependent.

Diab A, Jenq RR, Rizzuto GA, Cohen AD, Huggins DW, Merghoub T, Engelhorn ME, Guevara-Patiño JA, Suh D, Hubbard-Lucey VM, Kochman AA, Chen S, Zhong H, Wolchok JD, van den Brink MR, Houghton AN, Perales MA.

PLoS One. 2013 Dec 12;8(12):e82496. doi: 10.1371/journal.pone.0082496. eCollection 2013.

4.

Two Distinct Categories of Focal Deletions in Cancer Genomes.

Rajaram M, Zhang J, Wang T, Li J, Kuscu C, Qi H, Kato M, Grubor V, Weil RJ, Helland A, Borrenson-Dale AL, Cho KR, Levine DA, Houghton AN, Wolchok JD, Myeroff L, Markowitz SD, Lowe SW, Zhang M, Krasnitz A, Lucito R, Mu D, Powers RS.

PLoS One. 2013 Jun 21;8(6):e66264. doi: 10.1371/journal.pone.0066264. Print 2013.

5.

Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma.

Yuan J, Ku GY, Adamow M, Mu Z, Tandon S, Hannaman D, Chapman P, Schwartz G, Carvajal R, Panageas KS, Houghton AN, Wolchok JD.

J Immunother Cancer. 2013 Nov 18;1:20. doi: 10.1186/2051-1426-1-20. eCollection 2013.

6.

Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype.

Hirschhorn-Cymerman D, Budhu S, Kitano S, Liu C, Zhao F, Zhong H, Lesokhin AM, Avogadri-Connors F, Yuan J, Li Y, Houghton AN, Merghoub T, Wolchok JD.

J Exp Med. 2012 Oct 22;209(11):2113-26. doi: 10.1084/jem.20120532. Epub 2012 Sep 24.

7.

Innate immune response of human plasmacytoid dendritic cells to poxvirus infection is subverted by vaccinia E3 via its Z-DNA/RNA binding domain.

Cao H, Dai P, Wang W, Li H, Yuan J, Wang F, Fang CM, Pitha PM, Liu J, Condit RC, McFadden G, Merghoub T, Houghton AN, Young JW, Shuman S, Deng L.

PLoS One. 2012;7(5):e36823. doi: 10.1371/journal.pone.0036823. Epub 2012 May 14.

8.

Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.

Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, Rizzuto GA, Lazarus JJ, Pamer EG, Houghton AN, Merghoub T, Wolchok JD.

Cancer Res. 2012 Feb 15;72(4):876-86. doi: 10.1158/0008-5472.CAN-11-1792. Epub 2011 Dec 15.

9.

Myxoma virus induces type I interferon production in murine plasmacytoid dendritic cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-dependent pathway.

Dai P, Cao H, Merghoub T, Avogadri F, Wang W, Parikh T, Fang CM, Pitha PM, Fitzgerald KA, Rahman MM, McFadden G, Hu X, Houghton AN, Shuman S, Deng L.

J Virol. 2011 Oct;85(20):10814-25. doi: 10.1128/JVI.00104-11. Epub 2011 Aug 10. Erratum in: J Virol. 2011 Dec;85(23):12835.

10.

Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope.

Schaer DA, Li Y, Merghoub T, Rizzuto GA, Shemesh A, Cohen AD, Li Y, Avogadri F, Toledo-Crow R, Houghton AN, Wolchok JD.

PLoS One. 2011;6(6):e21214. doi: 10.1371/journal.pone.0021214. Epub 2011 Jun 22.

11.

Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice.

Orlandi F, Guevara-Patiño JA, Merghoub T, Wolchok JD, Houghton AN, Gregor PD.

Vaccine. 2011 May 9;29(20):3646-54. doi: 10.1016/j.vaccine.2011.03.017. Epub 2011 Mar 22.

PMID:
21435405
12.

Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.

Romano E, Rossi M, Ratzinger G, de Cos MA, Chung DJ, Panageas KS, Wolchok JD, Houghton AN, Chapman PB, Heller G, Yuan J, Young JW.

Clin Cancer Res. 2011 Apr 1;17(7):1984-97. doi: 10.1158/1078-0432.CCR-10-3421. Epub 2011 Feb 25. Erratum in: Clin Cancer Res. 2011 Jun 1;17(11):3851. Wolchock, Jedd D [corrected to Wolchok, Jedd D].

13.

Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.

Avogadri F, Merghoub T, Maughan MF, Hirschhorn-Cymerman D, Morris J, Ritter E, Olmsted R, Houghton AN, Wolchok JD.

PLoS One. 2010 Sep 10;5(9). pii: e12670. doi: 10.1371/journal.pone.0012670.

14.

Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.

Ginsberg BA, Gallardo HF, Rasalan TS, Adamow M, Mu Z, Tandon S, Bewkes BB, Roman RA, Chapman PB, Schwartz GK, Carvajal RD, Panageas KS, Terzulli SL, Houghton AN, Yuan JD, Wolchok JD.

Clin Cancer Res. 2010 Aug 1;16(15):4057-65. doi: 10.1158/1078-0432.CCR-10-1093. Epub 2010 Jul 20.

15.

Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.

Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-Cymmerman D, Kim SC, Diab A, Rizzuto G, Duan F, Perales MA, Merghoub T, Houghton AN, Wolchok JD.

PLoS One. 2010 May 3;5(5):e10436. doi: 10.1371/journal.pone.0010436.

16.

Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs.

Nakahara T, Uchi H, Lesokhin AM, Avogadri F, Rizzuto GA, Hirschhorn-Cymerman D, Panageas KS, Merghoub T, Wolchok JD, Houghton AN.

Blood. 2010 Jun 3;115(22):4384-92. doi: 10.1182/blood-2009-11-251231. Epub 2010 Feb 12.

17.

Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses.

Lin Y, Gallardo HF, Ku GY, Li H, Manukian G, Rasalan TS, Xu Y, Terzulli SL, Old LJ, Allison JP, Houghton AN, Wolchok JD, Yuan J.

Cytotherapy. 2009;11(7):912-22. doi: 10.3109/14653240903136987.

18.

Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right.

Ruby CE, Yates MA, Hirschhorn-Cymerman D, Chlebeck P, Wolchok JD, Houghton AN, Offner H, Weinberg AD.

J Immunol. 2009 Oct 15;183(8):4853-7. doi: 10.4049/jimmunol.0901112. Epub 2009 Sep 28.

19.

Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.

Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS, Xu Y, Li H, Vyas S, Mu Z, Chapman PB, Krown SE, Panageas K, Terzulli SL, Old LJ, Houghton AN, Wolchok JD.

Cancer Immun. 2009 Jun 5;9:5.

20.

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.

Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T, Cohen AD, Avogadri F, Lesokhin AM, Weinberg AD, Wolchok JD, Houghton AN.

J Exp Med. 2009 May 11;206(5):1103-16. doi: 10.1084/jem.20082205. Epub 2009 May 4.

21.

Immune rejection of mouse tumors expressing mutated self.

Duan F, Lin Y, Liu C, Engelhorn ME, Cohen AD, Curran M, Sakaguchi S, Merghoub T, Terzulli S, Wolchok JD, Houghton AN.

Cancer Res. 2009 Apr 15;69(8):3545-53. doi: 10.1158/0008-5472.CAN-08-2779. Epub 2009 Apr 7.

22.

Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response.

Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D, Zhong H, Panageas KS, Perales MA, Altan-Bonnet G, Wolchok JD, Houghton AN.

J Exp Med. 2009 Apr 13;206(4):849-66. doi: 10.1084/jem.20081382. Epub 2009 Mar 30.

23.

Development of effective vaccines for old mice in a tumor model.

Posnett DN, Engelhorn ME, Lin Y, Merghoub T, Duan F, Wolchok JD, Houghton AN.

Vaccine. 2009 Feb 11;27(7):1093-100. doi: 10.1016/j.vaccine.2008.11.112. Epub 2008 Dec 25.

24.

Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.

Saenger YM, Li Y, Chiou KC, Chan B, Rizzuto G, Terzulli SL, Merghoub T, Houghton AN, Wolchok JD.

Cancer Res. 2008 Dec 1;68(23):9884-91. doi: 10.1158/0008-5472.CAN-08-2233.

25.

Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation.

Jenq RR, King CG, Volk C, Suh D, Smith OM, Rao UK, Yim NL, Holland AM, Lu SX, Zakrzewski JL, Goldberg GL, Diab A, Alpdogan O, Penack O, Na IK, Kappel LW, Wolchok JD, Houghton AN, Perales MA, van den Brink MR.

Blood. 2009 Feb 12;113(7):1574-80. doi: 10.1182/blood-2008-05-155697. Epub 2008 Nov 14.

26.

Selective expression of inhibitory Fcgamma receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response.

Cassard L, Cohen-Solal JF, Fournier EM, Camilleri-Broët S, Spatz A, Chouaïb S, Badoual C, Varin A, Fisson S, Duvillard P, Boix C, Loncar SM, Sastre-Garau X, Houghton AN, Avril MF, Gresser I, Fridman WH, Sautès-Fridman C.

Int J Cancer. 2008 Dec 15;123(12):2832-9. doi: 10.1002/ijc.23870.

27.

Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.

Perales MA, Yuan J, Powel S, Gallardo HF, Rasalan TS, Gonzalez C, Manukian G, Wang J, Zhang Y, Chapman PB, Krown SE, Livingston PO, Ejadi S, Panageas KS, Engelhorn ME, Terzulli SL, Houghton AN, Wolchok JD.

Mol Ther. 2008 Dec;16(12):2022-9. doi: 10.1038/mt.2008.196. Epub 2008 Sep 16.

28.

Mechanisms of immunization against cancer using chimeric antigens.

Engelhorn ME, Guevara-Patiño JA, Merghoub T, Liu C, Ferrone CR, Rizzuto GA, Cymerman DH, Posnett DN, Houghton AN, Wolchok JD.

Mol Ther. 2008 Apr;16(4):773-81. doi: 10.1038/mt.2008.8. Epub 2008 Feb 26.

29.

Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag.

Felicetti P, Mennecozzi M, Barucca A, Montgomery S, Orlandi F, Manova K, Houghton AN, Gregor PD, Concetti A, Venanzi FM.

Cytotherapy. 2007;9(1):23-34. doi: 10.1080/14653240601048369.

PMID:
18236207
30.

A T-cell receptor associated with naturally occurring human tumor immunity.

Santomasso BD, Roberts WK, Thomas A, Williams T, Blachère NE, Dudley ME, Houghton AN, Posner JB, Darnell RB.

Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):19073-8.

31.

Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine.

Orlandi F, Venanzi FM, Concetti A, Yamauchi H, Tiwari S, Norton L, Wolchok JD, Houghton AN, Gregor PD.

Clin Cancer Res. 2007 Oct 15;13(20):6195-203.

32.

Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma.

Wolchok JD, Yuan J, Houghton AN, Gallardo HF, Rasalan TS, Wang J, Zhang Y, Ranganathan R, Chapman PB, Krown SE, Livingston PO, Heywood M, Riviere I, Panageas KS, Terzulli SL, Perales MA.

Mol Ther. 2007 Nov;15(11):2044-50. Epub 2007 Aug 28.

33.

Stage-IV melanoma and pulmonary metastases: factors predictive of survival.

Neuman HB, Patel A, Hanlon C, Wolchok JD, Houghton AN, Coit DG.

Ann Surg Oncol. 2007 Oct;14(10):2847-53. Epub 2007 Aug 7.

PMID:
17680317
34.

Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes.

Houghton CS, Engelhorn ME, Liu C, Song D, Gregor P, Livingston PO, Orlandi F, Wolchok JD, McCracken J, Houghton AN, Guevara-Patiño JA.

Vaccine. 2007 Jul 20;25(29):5330-42. Epub 2007 Jun 4.

PMID:
17570567
35.

Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.

Gilewski TA, Ragupathi G, Dickler M, Powell S, Bhuta S, Panageas K, Koganty RR, Chin-Eng J, Hudis C, Norton L, Houghton AN, Livingston PO.

Clin Cancer Res. 2007 May 15;13(10):2977-85.

36.

Tumor endothelial marker 8 enhances tumor immunity in conjunction with immnization against differentiation Ag.

Felicetti P, Mennecozzi M, Barucca A, Montgomery S, Orlandi F, Manova K, Houghton AN, Gregor PD, Concetti A, Venanzi FM.

Cytotherapy. 2007;9(1):23-34. Erratum in: Cytotherapy. 2007;9(2):205.

PMID:
17361485
37.

In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring.

Yuan J, Gallardo HF, Rasalan T, Ranganathan R, Wang J, Zhang Y, Panageas K, Stan R, Young JW, Houghton AN, Wolchok JD.

Cytotherapy. 2006;8(5):498-508. Erratum in: Cytotherapy. 2007;9(4):406.

PMID:
17050255
38.

Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains.

Ferrone CR, Perales MA, Goldberg SM, Somberg CJ, Hirschhorn-Cymerman D, Gregor PD, Turk MJ, Ramirez-Montagut T, Gold JS, Houghton AN, Wolchok JD.

Clin Cancer Res. 2006 Sep 15;12(18):5511-9.

39.

Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).

Krown SE, Niedzwiecki D, Hwu WJ, Hodgson L, Houghton AN, Haluska FG; Cancer and Leukemia Group B.

Cancer. 2006 Oct 15;107(8):1883-90.

40.

DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation.

Perales MA, Diab A, Cohen AD, Huggins DW, Guevara-Patiño JA, Hubbard VM, Engelhorn ME, Kochman AA, Eng JM, Mortazavi F, Alpdogan O, Terwey TH, Heller G, Wolchok JD, Houghton AN, van den Brink MR.

J Immunol. 2006 Sep 15;177(6):4159-67.

41.

Melanoma.

Houghton AN, Coit DG, Daud A, Dilawari RA, Dimaio D, Gollob JA, Haas NB, Halpern A, Johnson TM, Kashani-Sabet M, Kraybill WG, Lange JR, Martini M, Ross MI, Samlowski WE, Sener SF, Tanabe KK, Thompson JA, Trisal V, Urist MM, Walker MJ; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Aug;4(7):666-84. No abstract available.

PMID:
16884669
42.

Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo.

Uchi H, Stan R, Turk MJ, Engelhorn ME, Rizzuto GA, Goldberg SM, Wolchok JD, Houghton AN.

Adv Immunol. 2006;90:215-41. Review.

PMID:
16730265
43.

Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.

Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, Terwey TH, Kochman AA, Lu S, Miles RC, Sakaguchi S, Houghton AN, van den Brink MR.

J Immunol. 2006 Jun 1;176(11):6434-42.

44.

Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.

Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, Sakaguchi S, Houghton AN.

Cancer Res. 2006 May 1;66(9):4904-12.

45.

Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.

Hwu WJ, Panageas KS, Menell JH, Lamb LA, Aird S, Krown SE, Williams LJ, Chapman PB, Livingston PO, Wolchok JD, Houghton AN.

Cancer. 2006 Jun 1;106(11):2445-51.

46.

Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma.

Liao JC, Gregor P, Wolchok JD, Orlandi F, Craft D, Leung C, Houghton AN, Bergman PJ.

Cancer Immun. 2006 Apr 21;6:8.

47.

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity.

Guevara-Patiño JA, Engelhorn ME, Turk MJ, Liu C, Duan F, Rizzuto G, Cohen AD, Merghoub T, Wolchok JD, Houghton AN.

J Clin Invest. 2006 May;116(5):1382-90. Epub 2006 Apr 13.

48.

Langerhans-type dendritic cells genetically modified to express full-length antigen optimally stimulate CTLs in a CD4-dependent manner.

Yuan J, Latouche JB, Hodges J, Houghton AN, Heller G, Sadelain M, Riviere I, Young JW.

J Immunol. 2006 Feb 15;176(4):2357-65.

49.

Autoimmunity and tumor immunity induced by immune responses to mutations in self.

Engelhorn ME, Guevara-Patiño JA, Noffz G, Hooper AT, Lou O, Gold JS, Kappel BJ, Houghton AN.

Nat Med. 2006 Feb;12(2):198-206. Epub 2006 Jan 29.

PMID:
16444264
50.

Estimates of stage-specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma.

Ben-Porat L, Panageas KS, Hanlon C, Patel A, Halpern A, Houghton AN, Coit D.

Cancer. 2006 Jan 1;106(1):163-71.

Supplemental Content

Loading ...
Support Center